Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
NEW YORK, March 08, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (“Ophthotech”) (NASDAQ:OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al. (Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.
On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29.
Take Action: if you suffered a loss in Ophthotech you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
